All Shanghai Institute of Immunity and Infection articles
-
NewsProtective human monoclonal antibody targets a conserved site of spike glycoprotein of SARS-CoV-2 Omicron variants
Scientists report that mAb-39 greatly improved the neutralizing activity of anti-RBD antibody, the same type of EUA therapeutic monoclonal antibodies, against the highly neutralization-resistant Omicron variants.
